Blueprint Medicines Corporation (BPMC) stock surged 5.01% during intraday trading on Friday, continuing its upward momentum following the company's recent first-quarter earnings report and raised guidance. Despite missing earnings and revenue estimates, investors appear to be focusing on the company's strong product sales and optimistic outlook.
The biotech firm reported a wider-than-expected Q1 loss of 74 cents per share, compared to the anticipated loss of 42 cents. Revenues of $149.4 million, generated entirely from Ayvakit sales, also fell short of expectations. However, Ayvakit sales showed impressive growth, jumping 61% year-over-year to $149.4 million, driven by new patient starts and high compliance rates.
Blueprint Medicines raised its 2025 guidance for global Ayvakit net product revenues to $700-$720 million, up from the previous range of $680-$710 million. This increase, coupled with the company's long-term sales target of $2 billion for Ayvakit by 2030, seems to have bolstered investor confidence. Additionally, positive updates on the company's pipeline, including progress with BLU-808 for various indications, may be contributing to the stock's upward movement.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。